19 sep 25   genflow biosciences - genflow strengthens ip portfolio genflow biosciences plc | genf | 1.1 0 0.0% | mkt cap: 4.99m    rns number : 9356z genflow biosciences plc 19 september 2025       19, september 2025   genflow biosciences plc    genflow strengthens global ip portfolio with china patent examination filing for sirt6 variants in nash   genflow biosciences plc (lse:genf) (otcqb:genff) ("genflow" or "the company"), the only publicly listed longevity company in europe, today announces that it has filed a formal request for the examination of its patent application entitled sirt6 variants for nash in china.   the application covers proprietary variants of the sirt6 gene designed to address non-alcoholic steatohepatitis (nash), a severe progressive liver disease with limited treatment options. by pursuing examination in china, genflow is reinforcing its global intellectual property portfolio and furthering its commitment to developing innovative therapies for patients worldwide.   dr. eric leire, ceo of genflow, commented: "the filing of this examination request in china represents another significant step in protecting our technology in one of the world's largest healthcare markets. we are committed to advancing our research into sirt6-based therapies and believe that our approach holds strong potential to transform the treatment landscape for nash."   contacts genflow biosciences harbor access                          dr eric leire, ceo jonathan paterson, investor relations +32-477-495-881 +1 475 477 9401  jonathan.paterson@harbor-access.com   corporate brokers  capital plus partners ltd  jon critchley, +44 207 432 0501    about genflow biosciences   founded in 2020, genflow biosciences plc. (lse:genf) (otcqb:genff), a biotechnology company headquartered in the uk with r&d facilities in belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. genflow's lead compound, gf-1002, works through the delivery of a centenarian variant of the sirt6 gene which has yielded promising preclinical results. genflow's 12-month proof-of-concept clinical trial evaluating their sirt6-centenarian gene therapy in aged dogs began in march 2025. other programs planned for 2025, include a clinical trial that will explore the potential benefits of gf-1002 in treating mash (metabolic dysfunction-associated steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. please visit www.genflowbio.com  and follow the company on linkedin and x.   disclaimer the contents of this announcement have been prepared by, and are the sole responsibility of, the company. this announcement may contain forward-looking statements. the forward-looking statements include, but are not limited to, statements regarding the company's or the directors' expectations, hopes, beliefs, intentions or strategies regarding the future. in addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. the words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. forward-looking statements include all matters that are not historical facts. forward-looking statements are based on the current expectations and assumptions regarding the company, the business, the economy and other future conditions. because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. forward-looking statements are not guarantees of future performance and the company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. in addition, even if the company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions. any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. factors or events that could cause the company's actual plans or results to differ may emerge from time to time, and it is not possible for the company to predict all of them. the company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the prospectus regulation rules, the listing rules, the disclosure guidance and transparency rules of the fca or the uk market abuse regulation.       this information is provided by reach, the non-regulatory press release distribution service of rns, part of the london stock exchange. terms and conditions relating to the use and distribution of this information may apply. for further information, please contact rns@lseg.com or visit www.rns.com.  rns may use your ip address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. for further information about how rns and the london stock exchange use the personal data you provide us, please see our privacy policy.   end   nrapkfbkqbkdccd return to news summary

Label: Gestiegen